Jeffrey N. Weitzel, MD, director, Clinical Cancer Genetics, director, Cancer Screening & Prevention Program Network, professor, City of Hope, discusses the impact of gene mutations on treatment.
Weitzel believes risk-appropriate management is important. A decade of evidence shows that removing the ovaries of young BRCA carriers almost eliminates the risk of ovarian cancer, as well as breast cancer, adds Weitzel.
There are many challenges that Weitzel and his colleagues face as they try to integrate new genes, and for every gene, there is a chance of finding a variation that is less understood.
Jeffrey N. Weitzel, MD, director, Clinical Cancer Genetics, director, Cancer Screening & Prevention Program Network, professor, City of Hope, discusses the impact of gene mutations on treatment.
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More